FIELD: medicine.
SUBSTANCE: invention relates to biology and medicine and is aimed at the increase of efficiency of the tumour growth suppression with the application of recombinant human proteins, which bind with a receptor of cytokine TRAIL/Apo2L and trigger apoptotic death of tumour cells, without damaging normal cells. In particular the invention relates to a method of suppressing the tumour growth. The invention consists in the fact that the said recombinant proteins, binding with receptors of cytokine TRAIL/Apo2L, are applied in a combination with substances, which suppress resistance of the tumour cells to TRAIL proteins, and in addition to it cyclic peptide Cys-Arg-Gly-Asp-Lys-Gly-Pro-Asp-Cys is applied. It is supposed that the said peptide enhances the penetration of TRAIL from the vessels to the tumour cells.
EFFECT: application of a combination of recombinant TRAIL proteins and substances, which increase the sensitivity of the tumour cells to them, in a combination with the said peptide in accordance with the claimed invention, makes it possible to increase efficiency of the tumour growth suppression.
3 dwg, 3 ex
Title | Year | Author | Number |
---|---|---|---|
CSF1R-BASED CHIMERIC PROTEINS | 2018 |
|
RU2792239C2 |
TARGETED TGF BETA INHIBITION | 2015 |
|
RU2752424C2 |
ANTI-DR5 ANTIBODY AND USE THEREOF | 2018 |
|
RU2735956C1 |
HUMANIZED ANTIBODY AGAINST PD-1 AND ITS USE | 2019 |
|
RU2803460C2 |
NEW ANTIBODIES AND NUCLEOTIDE SEQUENCES AND THEIR USE | 2019 |
|
RU2802450C2 |
AMHRII BINDING COMPOUNDS FOR THE PREVENTION OR TREATMENT OF LUNG CANCERS | 2018 |
|
RU2797506C2 |
PHARMACEUTICAL COMPOSITION CONTAINING AS AN ACTIVE INGREDIENT A FUSED PROTEIN IN WHICH A TUMOR-PENETRATING PEPTIDE AND AN ANTIANGIOGENIC AGENT ARE FUSED FOR PREVENTING AND TREATING CANCER OR ANGIOGENESIS-RELATED DISEASES | 2016 |
|
RU2727238C2 |
MESOTHELINIC CAR RECEPTORS AND USE THEREOF | 2020 |
|
RU2822193C2 |
BISPECIFIC ANTIGEN-BINDING PROTEIN EGFR/CD16 | 2019 |
|
RU2792240C2 |
POLYVALENT BINDING PROTEINS FOR ACTIVATION OF NATURAL KILLER CELLS AND THEIR THERAPEUTIC APPLICATION FOR TREATMENT OF MALIGNANT NEOPLASM | 2018 |
|
RU2809125C2 |
Authors
Dates
2014-10-10—Published
2012-07-20—Filed